<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092037</url>
  </required_header>
  <id_info>
    <org_study_id>16-2462</org_study_id>
    <nct_id>NCT03092037</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics</brief_title>
  <official_title>Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will investigate the relationship between genetic variants and serum&#xD;
      contraceptive hormone levels, specifically the progestin etonogestrel. This study will&#xD;
      provide the foundation for future pharmacogenomic investigations of more commonly used&#xD;
      contraceptive methods with higher failure rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 700 reproductive age women (18-45) with an Etonogestrel (ENG) contraceptive&#xD;
      implant in place for more than 1 year will be enrolled. Participants will undergo a blood&#xD;
      draw for measurement of ENG concentration (serum) and genotyping (whole blood) and complete a&#xD;
      questionnaire regarding their demographics and contraceptive, gynecological, and obstetrical&#xD;
      history. The research investigators will also consent participants for use of their genetic&#xD;
      samples and clinical data in future unspecified research.&#xD;
&#xD;
      The serum samples will be de-identified for ENG analysis, which will be done using a liquid&#xD;
      chromatography-mass spectrometry method. Additional whole blood samples collected at the&#xD;
      enrollment visit will undergo DNA extraction. A candidate gene study was conducted using the&#xD;
      first 350 participants. The research investigators selected 120 genetic variants for 14&#xD;
      target genes involved in progestin metabolism, regulation, and function for this candidate&#xD;
      gene study. A Genome Wide Association Study will be performed using all 700 participants.&#xD;
      Genotyping will be performed using a custom MultiEthnic Global Array chip through the&#xD;
      Colorado Center for Personalized Medicine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of genetic variants in cases versus controls</measure>
    <time_frame>DNA extracted from whole blood specimens will be genotyped at the conclusion of enrollment, approximately 12 months.</time_frame>
    <description>Genetic variants will be analyzed using a Taqman microarray chip for 120 pre-selected variants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genome wide genotyping results</measure>
    <time_frame>DNA extracted from whole blood specimens will be genotyped at the conclusion of enrollment, approximately 15 months.</time_frame>
    <description>Participants will undergo genotyping using a custom MEGA chip at the Colorado Center for Personalized Medicine. Imputation of the chip results will be performed.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All participants (side-effects)</arm_group_label>
    <description>All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>The Investigators will collect serum and whole blood from participants.</description>
    <arm_group_label>All participants</arm_group_label>
    <arm_group_label>All participants (side-effects)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples will be collected at the enrollment visit and will undergo DNA extraction&#xD;
      using commercial QiagenÂ® kits in Dr. Christina Aquilante's laboratory.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will enroll 700 women of reproductive age (18-45 years) who have had an ENG&#xD;
        contraceptive implant in place for 12-36 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  women of reproductive age (18-45 years)&#xD;
&#xD;
          -  have had an ENG contraceptive implant in place for 12-36 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of medications or supplements in the past four weeks which could impact serum ENG&#xD;
             levels through inhibition or induction of CYP enzymes (specifically CYP-3A4)&#xD;
&#xD;
          -  Medical conditions that could impact baseline liver function (e.g. hepatitis,&#xD;
             cirrhosis)&#xD;
&#xD;
          -  Body mass index (BMI) less than 18.5&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Eligible participants must be females as we are studying the ENG contraceptive implant.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Lazorwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Dindinger</last_name>
    <phone>303-724-2013</phone>
    <email>eva.dindinger@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Morgan Moore</last_name>
    <phone>303-724-2013</phone>
    <email>morgan.moore@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Dindinger</last_name>
      <email>eva.dindinger@cuanschutz.edu</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Moore</last_name>
      <email>morgan.moore@cuanschutz.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aaron Lazorwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 10, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

